Ox-LDL, lysophospatidy choline platelet activating factor, IL-6 expression level and foam cell number with darappabdib treatment in early development of atherosclerosis: In vivo study for type 2 diabetes mellitus model

Insulin resistance in type 2 Diabetes Melitus (T2DM) is an extensive tissue damage condition due to vascular inflammation and oxidative stress. Lp-PLA2 has an antiinflammatory role as it hydrolyze atherogenesis mediators such as ox-LDL and platelet activating factor (PAF) and produces lysophosphatidylcholine (LysoPC) and oxidized fatty acid that have pro-inflammatory, proliferative and pro-atherogenic effect. Methods and results: This study aimed to discover the expression of ox-LDL level, LysoPC, PAF, IL-6 and foam cell numbers in aorta of T2DM in vivo model with darapladib treatment. True experimental laboratory and only post test with control group design using 30 Spraque Dowley rats that is divided into 3 main groups: normal, T2DM, and T2DM with the darapladib administration group. Each group consisted of 2 serials treatment time: 8-weeks and 16-weeks treatment groups. Parameter measured was IL-6, oxidized LDL and PAF, LysoPC, IL-6, foam cells and also blood glucose, lipid profile, and insulin plasma level. ANOVA test results showed that darapladib were significantly (p=0.000) lowering ox-LDL level, LysoPC, PAF, IL-6 expression and foam cells number in the aorta on T2DM in vivo model. Conclusions: This study concludes that dalapladib proved to have a role as anti atherogenesis on T2DM model.